X0202 SCHEDULE 13G 0000070858 XXXXXXXX LIVE Ordinary shares 03/31/2026 0001719714 Mereo BioPharma Group plc G6014T100 ONE CAVENDISH PLACE FOURTH FLOOR LONDON X0 W1G 0QF Rule 13d-1(b) BANK OF AMERICA CORP /DE/ b DE 0.00 40976460.00 0.00 40976460.00 40976460.00 5.1 HC "1. The security CUSIP corresponds to Mereo Biopharma Group PLC CUSIP International Numbering System (CINS) of the common stock. 2. The beneficial ownership calculation relies on the 798,078,829 outstanding shares disclosed in the Form 10-K by the issuer on March 19, 2026, which reports share totals as of March 18, 2026." Mereo BioPharma Group plc ONE CAVENDISH PLACE, FOURTH FLOOR, LONDON, UNITED KINGDOM, W1G 0QF. BANK OF AMERICA CORP /DE/ 100 N TRYON ST CHARLOTTE, NC 28255 Delaware N HC 40,976,460.00 5.1% 0.00 40,976,460.00 0.00 40,976,460.00 Y N Y N This statement on Schedule 13G is being filed by Bank of America Corporation on behalf of itself and its wholly owned subsidiaries BofA Securities, Inc., a broker dealer registered under section 15 of the Act (15 U.S.C. 78o); Bank of America N.A., a bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c); and Merrill Lynch International, a non-U.S. institution in accordance with section 240.13d-1(b)(1)(ii)(J). Y Y N By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11. BANK OF AMERICA CORP /DE/ /s/ Monica Yako 05/14/2026